Literature DB >> 9375013

In vitro infection and replication of hepatitis E virus in primary cynomolgus macaque hepatocytes.

A W Tam1, R White, P O Yarbough, B J Murphy, C P McAtee, R E Lanford, T R Fuerst.   

Abstract

An in vitro model was developed to replicate hepatitis E virus (HEV) in normal primary cynomolgus macaque hepatocytes using a hormonally defined, serum-free medium formulation. Primary hepatocytes were infected in tissue culture following isolation by collagenase treatment of liver wedge biopsy material. Viral replication was monitored by a highly strand-specific reverse transcription-polymerase chain reaction (RT-PCR) assay, which could detect the positive- and negative-strands of HEV RNA independently in a sensitive and specific manner. Several infectious HEV (Burma strain) inocula were titered by this RT-PCR assay, and a minimum effective infectious dose was determined. Appearance of newly replicated virus was demonstrated by detection of both strands of HEV RNA in experimentally infected hepatocytes as well as the genomic positive-strand viral RNA in the culture medium. Infectivity of the virus particles present in the media was confirmed by serial passage and replication of the virus in culture. Using this in vitro infection system, a neutralization assay was developed to assess the ability of anti-HEV antibodies to block virus infection of liver cells. Results presented in this report represent the first in vitro demonstration of a neutralizing anti-HEV antibody directed against the ORF2-encoded putative capsid protein.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9375013     DOI: 10.1006/viro.1997.8817

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  A bicistronic subgenomic mRNA encodes both the ORF2 and ORF3 proteins of hepatitis E virus.

Authors:  Judith Graff; Udana Torian; Hanh Nguyen; Suzanne U Emerson
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  ORF3 protein of hepatitis E virus is not required for replication, virion assembly, or infection of hepatoma cells in vitro.

Authors:  Suzanne U Emerson; Hanh Nguyen; Udana Torian; Robert H Purcell
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

3.  Hepatitis E vaccine.

Authors:  Rakesh Aggarwal; Shahid Jameel
Journal:  Hepatol Int       Date:  2008-04-10       Impact factor: 6.047

Review 4.  Hepatitis E virus: advances and challenges.

Authors:  Ila Nimgaonkar; Qiang Ding; Robert E Schwartz; Alexander Ploss
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-11-22       Impact factor: 46.802

5.  The 41-amino-acid C-terminal region of the hepatitis E virus ORF3 protein interacts with bikunin, a kunitz-type serine protease inhibitor.

Authors:  Shweta Tyagi; Milan Surjit; Sunil K Lal
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  New Methods in Tissue Engineering: Improved Models for Viral Infection.

Authors:  Vyas Ramanan; Margaret A Scull; Timothy P Sheahan; Charles M Rice; Sangeeta N Bhatia
Journal:  Annu Rev Virol       Date:  2014-11       Impact factor: 10.431

7.  Evidence of extrahepatic sites of replication of the hepatitis E virus in a swine model.

Authors:  T P Williams; C Kasorndorkbua; P G Halbur; G Haqshenas; D K Guenette; T E Toth; X J Meng
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

Review 8.  Hepatitis E: an overview and recent advances in vaccine research.

Authors:  Ling Wang; Hui Zhuang
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

Review 9.  New perspectives on hepatitis E.

Authors:  Kenneth C Hyams
Journal:  Curr Gastroenterol Rep       Date:  2002-08

10.  Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure.

Authors:  Tetsuo Yamashita; Yoshio Mori; Naoyuki Miyazaki; R Holland Cheng; Masato Yoshimura; Hideaki Unno; Ryoichi Shima; Kohji Moriishi; Tomitake Tsukihara; Tian Cheng Li; Naokazu Takeda; Tatsuo Miyamura; Yoshiharu Matsuura
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.